Healthcare >> Analyst Interviews >> June 7, 2001
BILL TANNER, Managing Director, joined the SG Cowen biotechnology team
in June 1999. He was previously with Vector Securities International
where he was a Biotechnology Analyst. Dr. Tanner began his career in
equities research as Vice President and Biotechnology Analyst at
Principal Financial Securities in Dallas. Prior to joining Principal, he
was a Research Associate in the Department of Pathology in the Center
for Immunology at Washington University Medical School. Dr. Tanner is
the recipient of a National Research Service Award from the National
Institutes of Health and a Postdoctoral Fellowship from the Juvenile
Diabetes Foundation. He received a BS, Animal Science, from Texas A&M
University; an MS, Nutrition, from Texas A&M University; a PhD,
Physiology, from Texas A&M University; and an MBA, from Washington
University. Profile
looking at in the biotech area and what you see going on?
Dr. Tanner: I think we see changes on a day-to-day basis in
